Ankush Banerjee22 Apr 2024, 18:19
This method addresses the challenge of viral mutation by targeting thousands of sections of the viral genome, ensuring efficacy against future variants. It also offers potential benefits for vulnerable groups such as infants and those with compromised immune systems, circumventing the limitations of traditional vaccines. Early trials on mice, including those lacking B and T cells, have shown promising results.